Molecure (FRA:1B1) Notes Receivable: €0.00 Mil (As of Sep. 2025)


FRA:1B1 Molecure SA FRA:1B1
37 GF Score
Price €1.25
! 3 Warning Signs
View Full Analysis

What is Molecure Notes Receivable?

Molecure FRA:1B1 -1.11% 37 Notes Receivable is €0.00 Mil as of Sep. 2025. GuruFocus rates FRA:1B1 with a GF Score™ of 37/100. The stock has 3 warning signs investors should review.

Molecure's Notes Receivable for the quarter that ended in Sep. 2025 was €0.00 Mil.

Molecure Notes Receivable Historical Data

* Premium members only.

The historical data trend for Molecure's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Molecure Notes Receivable Chart

Molecure Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Molecure Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:1B1
37GF Score
Molecure SA FRA:1B1
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Molecure Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of €0.00 Mil mean?
Molecure (FRA:1B1) has a Notes Receivable of €0.00 Mil as of Sep. 2025. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Molecure and its competitors.
Is Molecure's Notes Receivable too high?
Molecure's current Notes Receivable is €0.00 Mil. Overall, Molecure has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Molecure's Notes Receivable compare to VRTX and REGN?
Molecure's Notes Receivable of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Biotechnology company?
A good Notes Receivable depends on the Biotechnology industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Molecure and its competitors. Molecure's current Notes Receivable is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Molecure stock overvalued right now?
Molecure (FRA:1B1) has a current Notes Receivable of €0.00 Mil. The current Notes Receivable is €0.00 Mil. Molecure's overall GF Score™ is 37/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Molecure (FRA:1B1), the current Notes Receivable is €0.00 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Molecure Business Description

Other Exchanges MOC:Poland
Address Zwirki i Wigury 101, Warsaw, POL, 02-089
Molecure SA is a biopharmaceutical company engaged in discovering, developing, and commercializing novel therapeutics for neoplastic and inflammatory diseases. The company is focused on discovering and developing molecules with potential to become first-in-class or best-in-class drugs worldwide to treat unmet medical needs.
37GF Score

Get the complete analysis for FRA:1B1

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.25
Price